Yesterday's market selloff was very disappointing for investors. But it is worth remembering that every cloud has a silver lining.
On this occasion, the silver lining is that investors can now pick up shares at a discount to what they were going for just last week.
With that in mind, if you have $5,000 to invest in the share market, then it could be worth checking out the Australian stocks listed below that analysts rate as buys. Here's what they are saying about them:
Pilbara Minerals Ltd (ASX: PLS)
The first Australian stock that could be a buy with your $5,000 after the selloff is Pilbara Minerals. It is one of the world's leading lithium miners and the owner of the world class Pilgangoora Operation in the Pilbara.
Bell Potter is likely to see yesterday's decline (and 12 months of share price weakness) as a buying opportunity for investors. The broker currently has a buy rating and $3.00 price target on its shares. This suggests that potential upside of 35% for investors from current levels.
Its analysts think that lithium prices could improve meaningfully in the near term given its forecast for shortfalls from 2026. They said:
PLS operates a low-cost asset in a tier one jurisdiction, is diversifying through the lithium value chain, and provides a clean exposure to global lithium fundamentals and sentiment. While we expect lithium prices to remain volatile, we hold a robust EV-demand driven long-term market outlook. We believe higher prices are required to incentivise new sources of supply to moderate our forecast market shortfalls from 2026-27.
ResMed Inc. (ASX: RMD)
This sleep disorder treatment company could be another Australian stock to buy with your $5,000 after the market selloff.
Goldman Sachs certainly believes this is the case. In response to its second quarter update last week, the broker has retained its buy rating with an improved price target of $49.00. This implies potential upside of 26% for investors over the next 12 months.
The broker believes that the company's positive growth outlook means that its shares deserve to trade on better multiples. It said:
Our Buy recommendation on RMD is premised on (1) Ongoing robust new patient growth for CPAP therapy despite the market entry of GLP-1 drugs to treat OSA, (2) Further RMD market share gains, building on its #1 global market position, (3) Expansion of the OSA market in regions outside of the US. We believe the stock's current trading multiple is unjustified based on its growth outlook
